Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932410 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT02932410 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 165 participants.
The verdict
NCT02932410, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
Interventions
- DRUG Macitentan
- OTHER Standard-of-care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2025-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02932410
The ClinicalTrials.gov registry entry for NCT02932410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Macitentan is the first listed.
NCT02932410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02932410 about?
NCT02932410 is a clinical study titled "A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)". This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT02932410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2017-10-24. Estimated completion is 2025-11-27.
What interventions are being tested in trial NCT02932410?
The interventions under investigation include: Macitentan (DRUG), Standard-of-care (OTHER).
Who is sponsoring clinical trial NCT02932410?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.